Cadila Pharmaceuticals Ltd on Thursday announced the launch of Mycidac-C for affordable treatment of lung cancer which would be available in the Indian market by December.
The company said it took over a decade, huge investment and dedicate R&D teamwork to develop the world’s first innovative drug for treatment of lung cancer.
According to a WHO report, nearly 1.25 million people are diagnosed with lung cancer every year, worldwide. Around 30 per cent of them suffer from squamous Non Small Cell Lung Cancer. Lung cancer kills more people than the three next commonest cancers combined.
Mycidac-C is a research product for the patients suffering from Non Small Cell Lung Cancer. The drug has been approved for launch in India by the Drug Controller General of India, said Dr Rajiv I. Modi, Chairman and Managing Director.
“We expect it to be available in the Indian market by December 2013. Thereafter, we will introduce it in other regions like SAARC countries and European markets over the next five years.”
He said it is a breakthrough in the management of squamous cell NSCLC wherein no significant innovation has come about since the introduction of platinum containing doublet in 1983. Besides affordability and other advantages, Mycidac-C has no systemic side-effects during the treatment. Mycidac-C is to be used with platinum containing doublet therapy and can be administered easily by trained paramedics, thus further reducing the cost of hospitalisation associated with other cancer therapy.
The Ahmedabad-based Cadila Pharma, one of the largest privately-held pharmaceutical companies in India, had a turnover of Rs 1,200 crore in 2012-13. It was the first Indian company to get IND approval by USFDA for clinical trials to be conducted in India. Subsequently, the company has filed 5 INDs with the USFDA.
The company said it took over a decade, huge investment and dedicate R&D teamwork to develop the world’s first innovative drug for treatment of lung cancer.
According to a WHO report, nearly 1.25 million people are diagnosed with lung cancer every year, worldwide. Around 30 per cent of them suffer from squamous Non Small Cell Lung Cancer. Lung cancer kills more people than the three next commonest cancers combined.
Mycidac-C is a research product for the patients suffering from Non Small Cell Lung Cancer. The drug has been approved for launch in India by the Drug Controller General of India, said Dr Rajiv I. Modi, Chairman and Managing Director.
“We expect it to be available in the Indian market by December 2013. Thereafter, we will introduce it in other regions like SAARC countries and European markets over the next five years.”
He said it is a breakthrough in the management of squamous cell NSCLC wherein no significant innovation has come about since the introduction of platinum containing doublet in 1983. Besides affordability and other advantages, Mycidac-C has no systemic side-effects during the treatment. Mycidac-C is to be used with platinum containing doublet therapy and can be administered easily by trained paramedics, thus further reducing the cost of hospitalisation associated with other cancer therapy.
The Ahmedabad-based Cadila Pharma, one of the largest privately-held pharmaceutical companies in India, had a turnover of Rs 1,200 crore in 2012-13. It was the first Indian company to get IND approval by USFDA for clinical trials to be conducted in India. Subsequently, the company has filed 5 INDs with the USFDA.
No comments:
Post a Comment